References
- Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010;51:248–253.
- Hanson N, Leachman S. Safety issues in isotretinoin therapy. Semin Cutan Med Surg 2001;20:166–183.
- Karadag AS, Ertugrul DT, Tutal E, Akin KO. Isotretinoin influences pituitary hormone levels in acne patients. Acta Derm Venereol 2011;91:31–34.
- Palatsi R, Ruokonen A, Oikarinen A. Isotretinoin, tetracycline and circulating hormones in acne. Acta Derm Venereol 1997;77:394–396.
- Thiboutot D, Knaggs H, Gilliland K, Lin G. Activity of 5-alpha-reductase and 17-β-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology (Basel) 1998;196:38–42.
- Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007;357:1229–1237.
- Flückiger R. [A case from practice (256). 1. Right-sided gynecomastia possibly drug-induced (Roaccutan). 2. Status following excision and covering of a B-cell non-Hodgkin lymphoma of the skull. 3. Lumbar irritation syndrome of unclear origin]. Schweiz Rundsch Med Prax 1992;81:1370–1372.
- Zeller A. [Gynecomastia in a young man with acne]. Praxis (Bern 1994) 2000;89:1967–1969.